Metabolic Evaluation: Underused or Overdone?

  • Juan C. CalleEmail author
  • Manoj Monga


Stone recurrence is very common. The metabolic evaluation can help direct dietary and medical approaches to stone prevention. What is not known is whether a “directed approach” is more successful than an empiric approach. How many 24-h urine evaluations should be obtained? How often should one follow these patients? These issues and more will be addressed in this chapter.


Metabolic evaluation Stone recurrence Nephrolithiasis Stone composition 24-h urine collection 


  1. 1.
    Lotan Y. Economics and cost of care of stone disease. Adv Chronic Kidney Dis. 2009;16(1):5–10CrossRefPubMedGoogle Scholar
  2. 2.
    Stamatelou KK, Francis ME, Jones CA, Nyberg LM, Curhan GC, et al. Time trends in reported prevalence of kidney stones in the United States: 1976–1994. Kidney Int. 2003;63(5):1817–23.CrossRefPubMedGoogle Scholar
  3. 3.
    Lieske JC, Peña de la Vega LS, Slezak JM, Bergstralh EJ, Leibson CL, Ho KL, et al. Renal stone epidemiology in Rochester, Minnesota: an update. Kidney Int. 2006;69(4):760–4.CrossRefPubMedGoogle Scholar
  4. 4.
    Taylor EN, Stampfer MJ, Curhan GC. Obesity, weight gain, and the risk of kidney stones. J Am Med Assoc. 2005;293:455–62.CrossRefGoogle Scholar
  5. 5.
    Hall PM. Nephrolithiasis: treatment, causes, and prevention. Cleve Clin J Med. 2009;76(10):583–91.CrossRefPubMedGoogle Scholar
  6. 6.
    Coe FL, Keck J, Norton ER. The natural history of calcium urolithiasis. J Am Med Assoc. 1977;238(14):1519–23.CrossRefGoogle Scholar
  7. 7.
    Williams RE. Long-term survey of 538 patients with upper urinary tract stone. Br J Urol. 1963;35:416–37.CrossRefPubMedGoogle Scholar
  8. 8.
    Saigal CS, Joyce G, Timilsina AR. Direct and indirect costs of nephrolithiasis in an employed population: opportunity for disease management? Kidney Int. 2005 Oct;68(4):1808–14CrossRefPubMedGoogle Scholar
  9. 9.
    Kartha G, Calle JC, Marchini GS, Monga M. Impact of stone disease: chronic kidney disease and quality of life. Urol Clin North Am. 2013 Feb;40(1):135–47.CrossRefPubMedGoogle Scholar
  10. 10.
    Sakhaee K, Maalouf NM, Sinnott B. Kidney stones 2012: pathogenesis, diagnosis, and management. J Clin Endocrinol Metab. 2012;97:1847–60.CrossRefPubMedGoogle Scholar
  11. 11.
    Maalouf NM. Metabolic syndrome and the genesis of uric acid stones. J Ren Nutr. 2011;21:128–31.PubMedCentralCrossRefPubMedGoogle Scholar
  12. 12.
    Lieske JC, Kumar R, Collazo-Clavell ML. Nephrolithiasis after bariatric surgery for obesity. Semin Nephrol. 2008 Mar;28(2):163–73.PubMedCentralCrossRefPubMedGoogle Scholar
  13. 13.
    Suh JM, Cronan JJ, Monchik JM. Primary hyperparathyroidism: is there an increased prevalence of renal stone disease? Am J Roentgenol. 2008 Sep;191(3):908–11.CrossRefGoogle Scholar
  14. 14.
    Casella FJ, Allon M. The kidney in sarcoidosis. J Am Soc Nephrol. 1993 Mar;3(9):1555–62.PubMedGoogle Scholar
  15. 15.
    Buckalew VM Jr. Nephrolithiasis in renal tubular acidosis. J Urol.1989 Mar; 141(3 Pt 2):731–7.PubMedGoogle Scholar
  16. 16.
    Daudon M, Jungers P. Drug-induced renal calculi: epidemiology, prevention and management. Drugs 2004;64:245–75.CrossRefPubMedGoogle Scholar
  17. 17.
    Curhan GC, Willett WC, Rimm EB, Stampfer MJ. A prospective study of the intake of vitamins C and B6, and the risk of kidney stones in men. J Urol 1996;155:1847–51.CrossRefPubMedGoogle Scholar
  18. 18.
    U.S. Preventive Services Task Force. 2013. Accessed May 2013.
  19. 19.
    Goldfarb DS, Arowojolu O. Metabolic evaluation of first-time and recurrent stone formers. Urol Clin North Am. 2013 Feb;40(1):13–20.CrossRefPubMedGoogle Scholar
  20. 20.
    Peacock M. Primary hyperparathyroidism and the kidney: biochemical and clinical spectrum. J Bone Miner Res. 2002 Nov;17(Suppl 2):N87–94.Google Scholar
  21. 21.
    Beşbaş N, Oner A, Akhan O, Saatçi U, Bakkaloğlu A, Topaloğlu R. Nephrocalcinosis due to vitamin D intoxication. Turk J Pediatr. 1989 Jul-Sep;31(3):239–44.PubMedGoogle Scholar
  22. 22.
    Parmar MS. Kidney stones. BMJ. 2004 Jun 12;328(7453):1420–4.CrossRefPubMedGoogle Scholar
  23. 23.
    Goldfarb DS. Reconsideration of the 1988 NIH Consensus Statement on Prevention and Treatment of Kidney Stones: are the recommendations out of date? Rev Urol. 2002 Spring;4(2):53–60.PubMedCentralPubMedGoogle Scholar
  24. 24.
    Turk C, Knoll T, Petrik A, Sarica K, Skolarikos A, Straub M, Seitz C. Guidelines on Urolithiasis. 2013. Accessed May 2013.
  25. 25.
    Chandhoke PS. When is medical prophylaxis cost-effective for recurrent calcium stones? J Urol. 2002 Sep;168(3):937–40.CrossRefPubMedGoogle Scholar
  26. 26.
    Lotan Y, Cadeddu JA, Roerhborn CG, Pak CY, Pearle MS. Cost-effectiveness of medical management strategies for nephrolithiasis. J Urol. 2004 Dec; 172(6 Pt 1):2275–81.CrossRefPubMedGoogle Scholar
  27. 27.
    Lotan Y, Cadeddu JA, Pearle MS. International comparison of cost effectiveness of medical management strategies for nephrolithiasis. Urol Res. 2005 Jun;33(3):223–30.PubMedGoogle Scholar
  28. 28.
    Krambeck AE, Handa SE, Evan AP, Lingeman JE. Profile of the brushite stone former. J Urol. 2010 Oct;184(4):1367–71.PubMedCentralCrossRefPubMedGoogle Scholar
  29. 29.
    Pak CY, Peterson R, Poindexter JR. Adequacy of a single stone risk analysis in the medical evaluation of urolithiasis. J Urol. 2001 Feb;165(2):378–81.CrossRefPubMedGoogle Scholar
  30. 30.
    Castle SM, Cooperberg MR, Sadetsky N, Eisner BH, Stoller ML. Adequacy of a single 24-hour urine collection for metabolic evaluation of recurrent nephrolithiasis. J Urol. 2010 Aug;184(2):579–83.CrossRefPubMedGoogle Scholar
  31. 31.
    Parks JH, Goldfisher E, Asplin JR, Coe FL. A single 24-hour urine collection is inadequate for the medical evaluation of nephrolithiasis. J Urol. 2002 Apr;167(4):1607–12.CrossRefPubMedGoogle Scholar
  32. 32.
    Healy KA, Hubosky SG, Bagley D. 24-Hour urine collection in the metabolic evaluation of stone formers: Is one study adequate? J Endourol. 2013 Mar;27(3):374–8.CrossRefPubMedGoogle Scholar
  33. 33.
    Nayan M, Elkoushy MA, Andonian S. Variations between two 24-hour urine collections in patients presenting to a tertiary stone clinic. Can Urol Assoc J. 2012 Feb;6(1):30–3.PubMedCentralPubMedGoogle Scholar
  34. 34.
    Lein JW, Keane PM. Limitations of the oral calcium loading test in the management of the recurrent calcareous renal stone former. Am J Kidney Dis. 1983;3(1):76–9.PubMedGoogle Scholar
  35. 35.
    Pak CY, Sakhaee K, Pearle MS. Detection of absorptive hypercalciuria type I without the oral calcium load test. J Urol. 2011;185(3):915–9.CrossRefPubMedGoogle Scholar
  36. 36.
    Coe FL, Wise H, Parks JH, Asplin JR: Proportional reduction of urine supersaturation during nephrolithiasis treatment. J Urol. 2001;166(4):1247–51.CrossRefPubMedGoogle Scholar
  37. 37.
    Hong YH, Dublin N, Razack AH, Mohd MA, Husain R. Twenty-four hour and spot urine metabolic evaluations: correlations versus agreements. Urology. 2010 Jun;75(6):1294–8.CrossRefPubMedGoogle Scholar
  38. 38.
    Fink HA, Wilt TJ, Eidman KE, Garimella PS, MacDonald R, Rutks IR, et al. Recurrent nephrolithiasis in adults: comparative effectiveness of preventive medical strategies [Internet]. Comparative Effectiveness Review No. 61. Report No.: 12-EHC049–EF. Rockville: Agency for Healthcare Research and Quality (US); 2012.Google Scholar
  39. 39.
    Kijvikai K, de la Rosette JJ. Assessment of stone composition in the management of urinary stones. Nat Rev Urol. 2011 Feb;8(2):81–5.CrossRefPubMedGoogle Scholar
  40. 40.
    Basiri A, Taheri M, Taheri F. What is the state of the stone analysis techniques in urolithiasis? Urol J. 2012 Spring;9(2):445–54.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of Nephrology and HypertensionCleveland ClinicClevelandUSA
  2. 2.Stevan Streem Center of Endourology and Stone DiseaseCleveland ClinicClevelandUSA

Personalised recommendations